Home Healthcare Pharmaceuticals FLT3 Inhibitors Market

FLT3 Inhibitors Market Size, Share & Trends Analysis Report By Type (FLT3-ITD (Internal Tandem Duplication), FLT3-TKD (Tyrosine Kinase Domain)), By Product (Gilteritinib, Midostaurin, Quizartinib, Others), By End-User (Hospitals & Clinics, Research Laboratories) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR3448DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. FLT3 Inhibitors Market, By Type 2022-2034 (USD MILLION/ Units)
    1. FLT3-ITD (Internal Tandem Duplication)
    2. FLT3-TKD (Tyrosine Kinase Domain)
  2. FLT3 Inhibitors Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Gilteritinib
    2. Midostaurin
    3. Quizartinib
    4. Others
  3. FLT3 Inhibitors Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals & Clinics
    2. Research Laboratories
  4. Regional FLT3 Inhibitors Market
    1. North America
      1. North America FLT3 Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
      2. North America FLT3 Inhibitors Market By Product 2022-2034 (USD MILLION/ Units)
        1. Gilteritinib
        2. Midostaurin
        3. Quizartinib
        4. Others
      3. North America FLT3 Inhibitors Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Laboratories
      4. U.S.
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      5. Canada
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
    2. Europe
      1. Europe FLT3 Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
      2. Europe FLT3 Inhibitors Market By Product 2022-2034 (USD MILLION/ Units)
        1. Gilteritinib
        2. Midostaurin
        3. Quizartinib
        4. Others
      3. Europe FLT3 Inhibitors Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Laboratories
      4. U.K.
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      5. Germany
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      6. France
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      7. Spain
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      8. Italy
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      9. Russia
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      10. Nordic
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      11. Benelux
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      12. Rest of Europe
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
    3. APAC
      1. APAC FLT3 Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
      2. APAC FLT3 Inhibitors Market By Product 2022-2034 (USD MILLION/ Units)
        1. Gilteritinib
        2. Midostaurin
        3. Quizartinib
        4. Others
      3. APAC FLT3 Inhibitors Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Laboratories
      4. China
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      5. Korea
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      6. Japan
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      7. India
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      8. Australia
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      9. Taiwan
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      10. South East Asia
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      11. Rest of Asia-Pacific
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
    4. Middle East and Africa
      1. Middle East and Africa FLT3 Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
      2. Middle East and Africa FLT3 Inhibitors Market By Product 2022-2034 (USD MILLION/ Units)
        1. Gilteritinib
        2. Midostaurin
        3. Quizartinib
        4. Others
      3. Middle East and Africa FLT3 Inhibitors Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Laboratories
      4. UAE
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      5. Turkey
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      6. Saudi Arabia
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      7. South Africa
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      8. Egypt
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      9. Nigeria
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      10. Rest of MEA
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
    5. LATAM
      1. LATAM FLT3 Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
      2. LATAM FLT3 Inhibitors Market By Product 2022-2034 (USD MILLION/ Units)
        1. Gilteritinib
        2. Midostaurin
        3. Quizartinib
        4. Others
      3. LATAM FLT3 Inhibitors Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Laboratories
      4. Brazil
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      5. Mexico
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      6. Argentina
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      7. Chile
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      8. Colombia
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
      9. Rest of LATAM
        1. FLT3-ITD (Internal Tandem Duplication)
        2. FLT3-TKD (Tyrosine Kinase Domain)
        3. Gilteritinib
        4. Midostaurin
        5. Quizartinib
        6. Others
        7. Hospitals & Clinics
        8. Research Laboratories
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.